宋启斌
肿瘤
肿瘤中心主任兼肿瘤学教研室主任、一级主任医师/教授、硕士/博士研究生导师
肿瘤中心主任兼肿瘤学教研室主任、一级主任医师/教授、硕士/博士研究生导师
导师介绍
| 姓名 | 宋启斌 |
| 出生年月 | 1962/8/27 |
| 单位 | 武汉大学人民医院肿瘤中心 |
| 所属学科 | 临床医学-肿瘤学 |
| 职务、职称及头衔 | 肿瘤中心主任兼肿瘤学教研室主任、一级主任医师/教授、硕士/博士研究生导师 |
| qibinsong@whu.edu.cn | |
| 联系方式 | 027-88041911转82281或13517281931 |
| 研究方向 |
1.肺癌的基础与临床研究 2.肿瘤放射治疗基础与临床（放射物理、生物和技术） |
| 个人简介 | 本科毕业于中山医科大学临床医学专业（长学制），博士毕业于武汉大学，在美国MD Anderson癌症中心完成博士后训练。2002-2007年担任湖北省肿瘤医院副院长兼湖北省肿瘤研究所所长。2007年3月作为“特殊人才”引进调入武汉大学人民医院，担任肿瘤中心主任兼肿瘤学教研室主任，一级主任医师/教授、博士生导师，第5届国之名医—卓越贡献专家、国家教育部学位评审专家、国家癌症中心肺癌质控专家、国家抗肿瘤药物临床应用监测委员会委员、中国科协科技人才奖项评审专家、国家卫健委《肺癌诊疗指南》专家、人卫社教材《肺癌分册》副主编，中国医师协会肿瘤多学科诊疗专业委员会副主任委员兼总干事等多项国内、省内重要学术职务。兼任《Frontiers in Oncology》杂志执行主编（胸部肿瘤）、《肿瘤学》杂志副主编和《中华放射肿瘤学》杂志编委。主持国家自然科学基金3项、国家卫健委“重大疾病科技行动计划”、国家“863”、“973”子课题等多个科研项目；主持和参与国际国内多中心临床研究多项，累积研究经费逾1000万元。发表学术论文150余篇，其中SCI收录60余篇，主编专著6部。 |
| 学术任职与荣誉 |
中国医师协会肿瘤多学科诊疗专业委员会：副主任委员兼总干事 中国医促会胸部肿瘤分会：副主任委员 中国吴阶平医学会放疗专业委员会：副主任委员 中国吴阶平医学会肿瘤多学科诊疗专业委员会：副主任委员 世界华人肿瘤医师协会常务理事兼胸部肿瘤专业委员会：副主任委员 中国老年保健协会医学可视化专业委员会：副主任委员 中国临床肿瘤学会（CSCO）：常务理事 中国临床肿瘤学会（CSCO）老年肿瘤专业委会：副主任委员 中国临床肿瘤学会（CSCO）肺癌专家委员会：常委 中国临床肿瘤学会（CSCO）大数据专家委员会：常委 中国抗癌协会肺癌专业委员会：常委 中国抗癌协会科普专业委员会：常委 中国医促会肿瘤中西医专业委员会：常委 中国中部肿瘤放疗联盟（CC-RTOG）：侯任理事长 湖北省“323”肺癌质控专家委员会 主任委员 湖北省临床肿瘤学会（ESCO）：理事长兼肺癌专家委员会主任委员 湖北省抗癌协会：副理事长兼肺癌专业委员会委会主任委员 武汉医学会放射肿瘤治疗学分会：主任委员 武汉医学会肿瘤学分会：副主任委员 湖北省医学会肿瘤学分会：副主任委员 |
| 杂志编委 |
《Frontiers in Oncology》杂志 客座主编 《肿瘤学杂志》：副主编 《中华肿瘤学杂志》：编委 《中华放射肿瘤学杂志》：编委 《国际肿瘤学杂志》：编委 《武汉大学学报医学版》： 编委 《中国肺癌杂志》：编委 《中国肿瘤杂志》：编委 《微循环学杂志》：编委 《Chinese Medical Journal》：特约审稿人 |
| 教育履历 |
1980.09-1986.06广州中山医科大学医学系（6年制） 2003.09-2006.06中欧国际工商管理学院EMBA 2007.09-2010.06武汉大学医学院博士研究生 |
| 工作履历 |
1986.07-2002.11 湖北省肿瘤医院住院医师、主治医师、副主任医师 2002.12-2007.02 湖北省肿瘤医院主任医师、科主任、副院长 2006.10-2007.03 湖北省肿瘤医院副院长兼湖北省肿瘤研究所所长 2007.03-至今 武汉大学人民医院肿瘤中心主任兼肿瘤学教研室主任 |
| 成果获奖 |
人民日报、卫健委第五届“国之名医”——卓越建树专家 湖北省有突出贡献专家 湖北省新世纪高层次人才工程第二层次人选 湖北省抗击“非典”先进工作者 三维适形放疗同步化疗治疗局部晚期非小细胞肺癌 2002年获第8届全国肺癌大会和第6届中国临床肿瘤大会优秀论文一等奖（被《循证医学》评为国内10篇最佳肺癌文献之一） 三维适形放疗联合NP方案治疗局部晚期非小细胞肺癌 2005年获湖北省科技进步二等奖，第一完成人 |
| 代表性论著 |
[1] Chen,
L., Q. Zhou, P. Zhang, et al., Direct stimulation of de novo nucleotide
synthesis by O-GlcNAcylation[J]. Nat Chem Biol, 2023.DOI:
10.1038/s41589-023-01354-x. [2] Li, Y., J. Chen, B. Wang, et al., FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis[J]. Drug Resist Updat, 2023. 67: p. 100926.DOI: 10.1016/j.drup.2023.100926. [3] Cheng, Y., Z. Gao, T. Zhang, et al., Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance[J]. Cell Stem Cell, 2023. 30(1): p. 69-85.e7.DOI: 10.1016/j.stem.2022.12.003. [4] Chu, Y., Y. Yao, Q. Hu, et al., Riskscore Model Based on Oxidative Stress-Related Genes May Facilitate the Prognosis Evaluation for Patients With Colon Cancer[J]. Clin Transl Gastroenterol, 2023. 14(6): p. e00582.DOI: 10.14309/ctg.0000000000000582. [5] Ran, Z., L. Zhang, M. Dong, et al., O-GlcNAcylation: A Crucial Regulator in Cancer-Associated Biological Events[J]. Cell Biochem Biophys, 2023.DOI: 10.1007/s12013-023-01146-z. [6] Zhao, C., T. Xu, Y. Yao, et al., Comparison of case-based learning using Watson for oncology and traditional method in teaching undergraduate medical students[J]. Int J Med Inform, 2023. 177: p. 105117.DOI: 10.1016/j.ijmedinf.2023.105117. [7] Chen, L., Y. Weng, X. Cui, et al., Comprehensive analyses of a CD8(+) T cell infiltration related gene signature with regard to the prediction of prognosis and immunotherapy response in lung squamous cell carcinoma[J]. BMC Bioinformatics, 2023. 24(1): p. 238.DOI: 10.1186/s12859-023-05302-3. [8] Liu, Z., J. Wang, F. Liao, et al., Tumor-Educated Platelets Facilitate Thrombus Formation Through Migration[J]. Front Oncol, 2022. 12: p. 857865.DOI: 10.3389/fonc.2022.857865. [9] Fu, X., W. Tan, Q. Song, et al., BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies[J]. Front Cell Dev Biol, 2022. 10: p. 813457.DOI: 10.3389/fcell.2022.813457. [10] Ren, X., W. Wen, X. Fan, et al., COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas[J]. Cell, 2021. 184(23): p. 5838.DOI: 10.1016/j.cell.2021.10.023. [11] Zheng, S., Q. Song,P. Zhang, Metabolic Modifications, Inflammation, and Cancer Immunotherapy[J]. Front Oncol, 2021. 11: p. 703681.DOI: 10.3389/fonc.2021.703681. [12] Yu, L., H. Gong, Q. Li, et al., Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis[J]. J Oncol, 2021. 2021: p. 8849039.DOI: 10.1155/2021/8849039. [13] Yu, D., W. Hu, L. Chen, et al., Effect of radiotherapy interruption due to COVID-19 outbreak[J]. Radiother Oncol, 2021. 155: p. 1-2.DOI: 10.1016/j.radonc.2020.09.055. [14] Yang, S., Y. Yao, Y. Dong, et al., Prediction of Radiation Pneumonitis Using Genome-Scale Flux Analysis of RNA-Seq Derived From Peripheral Blood[J]. Front Med (Lausanne), 2021. 8: p. 715961.DOI: 10.3389/fmed.2021.715961. [15] Tan, W., P. Jiang, W. Zhang, et al., Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation[J]. Mol Cell, 2021. 81(9): p. 1890-1904.e7.DOI: 10.1016/j.molcel.2021.02.009. [16] Liu, C., K. Song, Q. Hu, et al., Having gastroesophageal cancer is associated with increased risk of severe COVID-19-related events in patients with digestive tract cancer: A multicenter, retrospective, cohort study[J]. Int J Cancer, 2021. 148(7): p. 1789-1793.DOI: 10.1002/ijc.33452. [17] Lei, T., J. Li, H. Zhong, et al., Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis[J]. Front Oncol, 2021. 11: p. 680615.DOI: 10.3389/fonc.2021.680615. [18] He, H., T. Xu, P. Li, et al., Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review[J]. Front Oncol, 2021. 11: p. 782646.DOI: 10.3389/fonc.2021.782646. [19] Zuo, H., L. Chen, N. Li, et al., Identification of a Ubiquitination-Related Gene Risk Model for Predicting Survival in Patients With Pancreatic Cancer[J]. Front Genet, 2020. 11: p. 612196.DOI: 10.3389/fgene.2020.612196. [20] Wu, J., H. Zhang, L. Li, et al., A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis[J]. Cancer Commun (Lond), 2020. 40(7): p. 301-312.DOI: 10.1002/cac2.12067. [21] Liu, C., L. Li, K. Song, et al., A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study[J]. J Immunother Cancer, 2020. 8(2).DOI: 10.1136/jitc-2020-001314. [22] Hu, Z., S. Mi, T. Zhao, et al., BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites[J]. Embo j, 2020. 39(12): p. e104133.DOI: 10.15252/embj.2019104133. [23] Gong, H., H. Feng, L. Yu, et al., Coronavirus Disease 2019 Infection Among Medical Staff in Wuhan: A Retrospective Study From a Single Center[J]. Chest, 2020. 158(4): p. 1409-1412.DOI: 10.1016/j.chest.2020.05.529. [24] Peng, Y., Q. Liao, W. Tan, et al., The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors[J]. Nat Commun, 2019. 10(1): p. 1224.DOI: 10.1038/s41467-019-09232-8. [25] Yao, Y., Z. Zheng,Q. Song, Mesenchymal stem cells: A double-edged sword in radiation-induced lung injury[J]. Thorac Cancer, 2018. 9(2): p. 208-217.DOI: 10.1111/1759-7714.12573. |
| Name | Qibin Song |
| Date of birth | August 27th, 1962 |
| Department | Cancer Center |
| Title | Professor/Chief physician |
| qibinsong@163.com | |
| TEL | Cell:13517281931 Work:027-88041911-82281 |
| Research Direction |
1.The
basic and clinical research of lung cancer. 2.The basic and clinical research of radiotherapy. |
| Personal Profile |
Dr.
Qibin Song, MD, is a distinguished physician-scientist and board-certified
medical oncologist with specialized expertise in lung cancer treatment. He is
currently spearheading the cancer program at Renmin Hospital of Wuhan
University and holds a professorship in oncology at the same
university. Dr. Song is renowned for his treatment of diverse types of lung cancer, utilizing a variety of therapeutic approaches such as radiotherapy, chemotherapy, immunotherapy, targeted therapy, or often a fusion of these treatments. He seamlessly integrates his research proficiency in lung cancer's molecular biology with his commitment to patient-centered care, thereby facilitating enhanced outcomes for those battling lung cancer. Dr. Song's academic journey began at Sun Yat-sen University in China, where he earned his MD in medicine and completed his residency in internal medicine. He subsequently pursued a medical oncology fellowship and postdoctoral fellowships at Wuhan University, China. Prior to his current role, he spent a decade at Hubei Cancer Hospital. Here, he devoted his career to lung cancer research and treatment as a clinician investigator while also serving as the hospital's vice-president. His contributions to the field were recognized with his appointment as Director of the Cancer Center at Renmin Hospital of Wuhan University. A leading light in the field of lung cancer research, Dr. Song's breakthrough discovery was a revolutionary treatment for stage III NSCLC patients, involving a combination of 3DCRT with NP regimen chemotherapy. His present research undertakings delve into cancer metabolism and DNA damage repair in lung cancer, results of which are fostering innovative, precision-based treatment strategies. As the leader of the cancer center, Dr. Song not only pioneers in groundbreaking research but also supervises clinical research in oncology. |
| Selected Publications |
[1] Chen,
L., Q. Zhou, P. Zhang, et al., Direct stimulation of de novo nucleotide
synthesis by O-GlcNAcylation[J]. Nat Chem Biol, 2023.DOI:
10.1038/s41589-023-01354-x. [2] Li, Y., J. Chen, B. Wang, et al., FOXK2 affects cancer cell response to chemotherapy by promoting nucleotide de novo synthesis[J]. Drug Resist Updat, 2023. 67: p. 100926.DOI: 10.1016/j.drup.2023.100926. [3] Cheng, Y., Z. Gao, T. Zhang, et al., Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance[J]. Cell Stem Cell, 2023. 30(1): p. 69-85.e7.DOI: 10.1016/j.stem.2022.12.003. [4] Chu, Y., Y. Yao, Q. Hu, et al., Riskscore Model Based on Oxidative Stress-Related Genes May Facilitate the Prognosis Evaluation for Patients With Colon Cancer[J]. Clin Transl Gastroenterol, 2023. 14(6): p. e00582.DOI: 10.14309/ctg.0000000000000582. [5] Ran, Z., L. Zhang, M. Dong, et al., O-GlcNAcylation: A Crucial Regulator in Cancer-Associated Biological Events[J]. Cell Biochem Biophys, 2023.DOI: 10.1007/s12013-023-01146-z. [6] Zhao, C., T. Xu, Y. Yao, et al., Comparison of case-based learning using Watson for oncology and traditional method in teaching undergraduate medical students[J]. Int J Med Inform, 2023. 177: p. 105117.DOI: 10.1016/j.ijmedinf.2023.105117. [7] Chen, L., Y. Weng, X. Cui, et al., Comprehensive analyses of a CD8(+) T cell infiltration related gene signature with regard to the prediction of prognosis and immunotherapy response in lung squamous cell carcinoma[J]. BMC Bioinformatics, 2023. 24(1): p. 238.DOI: 10.1186/s12859-023-05302-3. [8] Liu, Z., J. Wang, F. Liao, et al., Tumor-Educated Platelets Facilitate Thrombus Formation Through Migration[J]. Front Oncol, 2022. 12: p. 857865.DOI: 10.3389/fonc.2022.857865. [9] Fu, X., W. Tan, Q. Song, et al., BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies[J]. Front Cell Dev Biol, 2022. 10: p. 813457.DOI: 10.3389/fcell.2022.813457. [10] Ren, X., W. Wen, X. Fan, et al., COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas[J]. Cell, 2021. 184(23): p. 5838.DOI: 10.1016/j.cell.2021.10.023. [11] Zheng, S., Q. Song,P. Zhang, Metabolic Modifications, Inflammation, and Cancer Immunotherapy[J]. Front Oncol, 2021. 11: p. 703681.DOI: 10.3389/fonc.2021.703681. [12] Yu, L., H. Gong, Q. Li, et al., Survival Analysis of Radiation Therapy in Ovarian Cancer: A SEER Database Analysis[J]. J Oncol, 2021. 2021: p. 8849039.DOI: 10.1155/2021/8849039. [13] Yu, D., W. Hu, L. Chen, et al., Effect of radiotherapy interruption due to COVID-19 outbreak[J]. Radiother Oncol, 2021. 155: p. 1-2.DOI: 10.1016/j.radonc.2020.09.055. [14] Yang, S., Y. Yao, Y. Dong, et al., Prediction of Radiation Pneumonitis Using Genome-Scale Flux Analysis of RNA-Seq Derived From Peripheral Blood[J]. Front Med (Lausanne), 2021. 8: p. 715961.DOI: 10.3389/fmed.2021.715961. [15] Tan, W., P. Jiang, W. Zhang, et al., Posttranscriptional regulation of de novo lipogenesis by glucose-induced O-GlcNAcylation[J]. Mol Cell, 2021. 81(9): p. 1890-1904.e7.DOI: 10.1016/j.molcel.2021.02.009. [16] Liu, C., K. Song, Q. Hu, et al., Having gastroesophageal cancer is associated with increased risk of severe COVID-19-related events in patients with digestive tract cancer: A multicenter, retrospective, cohort study[J]. Int J Cancer, 2021. 148(7): p. 1789-1793.DOI: 10.1002/ijc.33452. [17] Lei, T., J. Li, H. Zhong, et al., Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis[J]. Front Oncol, 2021. 11: p. 680615.DOI: 10.3389/fonc.2021.680615. [18] He, H., T. Xu, P. Li, et al., Anti-PD-1 Immunotherapy Combined With Stereotactic Body Radiation Therapy and GM-CSF as Salvage Therapy in a PD-L1-Positive Patient With Refractory Metastatic Thyroid Hürthle Cell Carcinoma: A Case Report and Literature Review[J]. Front Oncol, 2021. 11: p. 782646.DOI: 10.3389/fonc.2021.782646. [19] Zuo, H., L. Chen, N. Li, et al., Identification of a Ubiquitination-Related Gene Risk Model for Predicting Survival in Patients With Pancreatic Cancer[J]. Front Genet, 2020. 11: p. 612196.DOI: 10.3389/fgene.2020.612196. [20] Wu, J., H. Zhang, L. Li, et al., A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis[J]. Cancer Commun (Lond), 2020. 40(7): p. 301-312.DOI: 10.1002/cac2.12067. [21] Liu, C., L. Li, K. Song, et al., A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study[J]. J Immunother Cancer, 2020. 8(2).DOI: 10.1136/jitc-2020-001314. [22] Hu, Z., S. Mi, T. Zhao, et al., BGL3 lncRNA mediates retention of the BRCA1/BARD1 complex at DNA damage sites[J]. Embo j, 2020. 39(12): p. e104133.DOI: 10.15252/embj.2019104133. [23] Gong, H., H. Feng, L. Yu, et al., Coronavirus Disease 2019 Infection Among Medical Staff in Wuhan: A Retrospective Study From a Single Center[J]. Chest, 2020. 158(4): p. 1409-1412.DOI: 10.1016/j.chest.2020.05.529. [24] Peng, Y., Q. Liao, W. Tan, et al., The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors[J]. Nat Commun, 2019. 10(1): p. 1224.DOI: 10.1038/s41467-019-09232-8. [25] Yao, Y., Z. Zheng,Q. Song, Mesenchymal stem cells: A double-edged sword in radiation-induced lung injury[J]. Thorac Cancer, 2018. 9(2): p. 208-217.DOI: 10.1111/1759-7714.12573. |
武汉大学人民医院
湖北省人民医院